BB Biotech AG (BION) - Net Assets

Latest as of March 2026: CHF2.63 Billion CHF ≈ $3.33 Billion USD

Based on the latest financial reports, BB Biotech AG (BION) has net assets worth CHF2.63 Billion CHF (≈ $3.33 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF2.64 Billion ≈ $3.34 Billion USD) and total liabilities (CHF7.86 Million ≈ $9.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BB Biotech AG assets under control for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF2.63 Billion
% of Total Assets	99.7%
Annual Growth Rate	1.65%
5-Year Change	-15.51%
10-Year Change	-7.47%
Growth Volatility	25.61

BB Biotech AG - Net Assets Trend (2003–2025)

This chart illustrates how BB Biotech AG's net assets have evolved over time, based on quarterly financial data. Check BION tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for BB Biotech AG (2003–2025)

The table below shows the annual net assets of BB Biotech AG from 2003 to 2025. For live valuation and market cap data, see BION market cap overview.

Year	Net Assets	Change
2025-12-31	CHF2.78 Billion ≈ $3.51 Billion	+21.54%
2024-12-31	CHF2.29 Billion ≈ $2.89 Billion	-1.59%
2023-12-31	CHF2.32 Billion ≈ $2.94 Billion	-13.51%
2022-12-31	CHF2.69 Billion ≈ $3.40 Billion	-18.33%
2021-12-31	CHF3.29 Billion ≈ $4.16 Billion	-15.67%
2020-12-31	CHF3.90 Billion ≈ $4.93 Billion	+14.95%
2019-12-31	CHF3.39 Billion ≈ $4.29 Billion	+17.63%
2018-12-31	CHF2.88 Billion ≈ $3.65 Billion	-18.49%
2017-12-31	CHF3.54 Billion ≈ $4.47 Billion	+17.84%
2016-12-31	CHF3.00 Billion ≈ $3.80 Billion	-24.51%
2015-12-31	CHF3.98 Billion ≈ $5.03 Billion	+13.90%
2014-12-31	CHF3.49 Billion ≈ $4.42 Billion	+64.83%
2013-12-31	CHF2.12 Billion ≈ $2.68 Billion	+71.71%
2012-12-31	CHF1.23 Billion ≈ $1.56 Billion	+23.19%
2011-12-31	CHF1.00 Billion ≈ $1.27 Billion	-18.88%
2010-12-31	CHF1.23 Billion ≈ $1.56 Billion	-18.56%
2009-12-31	CHF1.52 Billion ≈ $1.92 Billion	+0.76%
2008-12-31	CHF1.50 Billion ≈ $1.90 Billion	-14.85%
2007-12-31	CHF1.77 Billion ≈ $2.23 Billion	-21.56%
2006-12-31	CHF2.25 Billion ≈ $2.85 Billion	-1.18%
2005-12-31	CHF2.28 Billion ≈ $2.88 Billion	+19.09%
2004-12-31	CHF1.91 Billion ≈ $2.42 Billion	-1.28%
2003-12-31	CHF1.94 Billion ≈ $2.45 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to BB Biotech AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 282.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CHF2.78 Billion	99.90%
Common Stock	CHF11.08 Million	0.40%
Total Equity	CHF2.78 Billion	100.00%

BB Biotech AG Competitors by Market Cap

The table below lists competitors of BB Biotech AG ranked by their market capitalization.

Company	Market Cap
China Resources Double-Crane Pharmaceutical Co Ltd SHG:600062	$2.48 Billion
China Huarong Asset Management Co. Ltd F:CHE	$2.48 Billion
Lechwerke AG F:LEC	$2.48 Billion
Talos Energy NYSE:TALO	$2.48 Billion
Artois Nom. PA:ARTO	$2.48 Billion
Banque Cantonale du Valais SW:WKBN	$2.48 Billion
Huada Automotive Tech Corp Ltd SHG:603358	$2.48 Billion
Lucid Group Inc NASDAQ:LCID	$2.47 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BB Biotech AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,286,292,000 to 2,778,785,000, a change of 492,493,000 (21.5%).
Net income of 578,133,000 contributed positively to equity growth.
Dividend payments of 98,487,000 reduced retained earnings.
Share repurchases of 5,037,000 reduced equity.
New share issuances of 17,884,000 increased equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CHF578.13 Million	+20.81%
Dividends Paid	CHF98.49 Million	-3.54%
Share Repurchases	CHF5.04 Million	-0.18%
Share Issuances	CHF17.88 Million	+0.64%
Total Change	CHF-	21.54%

Book Value vs Market Value Analysis

This analysis compares BB Biotech AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.01x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 3.41x to 1.01x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2003-12-31	CHF14.94	CHF50.90	x
2004-12-31	CHF15.26	CHF50.90	x
2005-12-31	CHF18.93	CHF50.90	x
2006-12-31	CHF18.91	CHF50.90	x
2007-12-31	CHF16.61	CHF50.90	x
2008-12-31	CHF17.00	CHF50.90	x
2009-12-31	CHF18.29	CHF50.90	x
2010-12-31	CHF15.64	CHF50.90	x
2011-12-31	CHF13.99	CHF50.90	x
2012-12-31	CHF21.06	CHF50.90	x
2013-12-31	CHF37.18	CHF50.90	x
2014-12-31	CHF61.65	CHF50.90	x
2015-12-31	CHF71.21	CHF50.90	x
2016-12-31	CHF54.34	CHF50.90	x
2017-12-31	CHF63.93	CHF50.90	x
2018-12-31	CHF52.07	CHF50.90	x
2019-12-31	CHF61.25	CHF50.90	x
2020-12-31	CHF70.18	CHF50.90	x
2021-12-31	CHF59.31	CHF50.90	x
2022-12-31	CHF48.52	CHF50.90	x
2023-12-31	CHF42.36	CHF50.90	x
2024-12-31	CHF41.70	CHF50.90	x
2025-12-31	CHF50.39	CHF50.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently BB Biotech AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 20.81%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 98.49%
• Asset Turnover: 0.21x
• Equity Multiplier: 1.00x
Recent ROE (20.81%) is above the historical average (6.74%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2003	9.25%	92.67%	0.10x	1.02x	CHF-14.59 Million
2004	10.59%	94.90%	0.11x	1.00x	CHF11.31 Million
2005	13.95%	95.59%	0.13x	1.10x	CHF90.00 Million
2006	13.20%	93.50%	0.12x	1.13x	CHF72.11 Million
2007	-15.02%	-21081.10%	0.00x	1.18x	CHF-442.13 Million
2008	3.01%	64.39%	0.04x	1.08x	CHF-105.13 Million
2009	2.42%	67.46%	0.04x	1.00x	CHF-115.00 Million
2010	-11.85%	0.00%	-0.10x	1.12x	CHF-269.83 Million
2011	-6.50%	0.00%	0.00x	1.15x	CHF-165.31 Million
2012	29.81%	97.62%	0.27x	1.11x	CHF244.43 Million
2013	43.98%	99.35%	0.42x	1.04x	CHF719.95 Million
2014	42.09%	99.58%	0.42x	1.01x	CHF1.12 Billion
2015	16.41%	99.03%	0.16x	1.04x	CHF255.00 Million
2016	-26.71%	0.00%	-0.25x	1.07x	CHF-1.10 Billion
2017	19.43%	99.20%	0.19x	1.03x	CHF333.64 Million
2018	-16.34%	0.00%	-0.15x	1.07x	CHF-759.79 Million
2019	19.97%	98.86%	0.19x	1.05x	CHF338.13 Million
2020	17.78%	98.85%	0.18x	1.02x	CHF302.42 Million
2021	-12.33%	0.00%	-0.11x	1.11x	CHF-733.16 Million
2022	-13.32%	0.00%	-0.12x	1.14x	CHF-626.43 Million
2023	-8.89%	-590305.71%	0.00x	1.14x	CHF-438.93 Million
2024	3.32%	67.99%	0.05x	1.05x	CHF-152.73 Million
2025	20.81%	98.49%	0.21x	1.00x	CHF300.25 Million

Industry Comparison

This section compares BB Biotech AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $42,203,807
Average return on equity (ROE) among peers: -72.76%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
BB Biotech AG (BION)	CHF2.63 Billion	9.25%	0.00x	$2.48 Billion
Addex Therapeutics Ltd (ADXN)	$77.58 Million	-55.03%	0.14x	$6.98 Million
Bachem Holding AG (BANB)	$1.17 Billion	8.61%	0.18x	$5.42 Billion
Bioversys AG (BIOV)	$59.81 Million	-36.50%	0.52x	$161.41 Million
Basilea Pharmaceutica AG (BSLN)	$112.31 Million	-75.82%	0.81x	$686.09 Million
Idorsia Ltd (IDIA)	$-1.21 Billion	0.00%	0.00x	$1.03 Billion
MINDMAZE THERAPEUTICS HOLDING SA (MMTX)	$86.00K	-1.16%	0.08x	$46.82 Million
Molecular Partners AG (MOLN)	$148.48 Million	-1.54%	0.31x	$145.86 Million
Newron Pharmaceuticals SpA (NWRN)	$3.11 Million	-479.59%	15.25x	$297.11 Million
Relief Therapeutics Holding AG (RLF)	$20.95 Million	-13.78%	0.48x	$36.33 Million

About BB Biotech AG

SW:BION Switzerland Biotechnology

Market Cap

$3.55 Billion

CHF2.81 Billion CHF

Market Cap Rank

#5415 Global

#80 in Switzerland

Share Price

CHF50.90

Change (1 day)

-0.39%

52-Week Range

CHF31.25 - CHF52.40

All Time High

CHF78.42